RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shortie is capping the AskHi macman1519;
I hope that your golf game went well.
As to my thoughts about Dr. Frost, they are quite mixed. Dr. Frost is quite bright and very well connected. He is a company builder. His current effort is Opko Health, Inc., ticker OPK. Opko Health does have focus on oncology and urology via subsidiaries BioReference Laboratories and GenPath Diagnostics. They offer healthcare providers a single source for all laboratory testing needs in primary care and specialty health care. At first glance this would make Dr Frost's Opko Health seem like a good choice for a long term joint venture partner for the bladder and prostate oncology indications.
A big concern for me is that Dr Frost is getting a bit elderly and I don't see the concern or depth of management at Opko Health for it to survive and grow without him. He does not have any children and is a very generous philanthropist. I believe that the company will quickly lose focus without him and will be broken up and sold off to fund his favorite charity organizations. What hands would that leave the oncology treatment division? Maybe left in inept or unfriendly hands until the joint venture expires. Not an great outcome for Theralase.
Another big concern for me is that Opko Heath is too small for our long term needs. I believe that with further great clinical results and several additional indications, Theralase value will be many times the market cap of Opko, they will be of no merger value to us. Maybe the other way around.
Therefore I would look elsewhere. My preference for a partner would be a very large diversified firm that is solid, and could afford to adequately fund us until we wanted to seek the possibility of a merger for stock so as not to trigger forced tax consequences. A great win for all. To much to hope for?
Thanks;
made2last